Gene · 6135
RPL11: ribosomal protein L11
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. RPL11: ribosomal protein L11. Genes, record 6135. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6135
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P62913 | Large ribosomal subunit protein uL5 | 178 | 168 | Ensembl, GeneID, HGNC |
Source UniProt
Patents28
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 61972 | P62913 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 9823 | P62913 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 9823 | P62913 | Espacenet |
| WO 2024240908 A1 | 2024-11-28 | 36 | P62913 | Espacenet |
| JP 2022165557 A | 2022-11-01 | 9 | P62913 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 73929 | P62913 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 176900 | P62913 | Espacenet |
| WO 2020043864 A1 | 2020-03-05 | 2113 | P62913 | Espacenet |
| JP 2019054813 A | 2019-04-11 | 242407 | P62913 | Espacenet |
| JP 2018036233 A | 2018-03-08 | 11 | P62913 | Espacenet |
1 to 10 of 28
See all 28 patentsDrugs9
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ATALUREN | CHEMBL256997 | 80S Ribosome modulator | MODULATOR | ChEMBL |
| CITATUZUMAB BOGATOX | CHEMBL1743000 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| CYCLOHEXIMIDE | CHEMBL123292 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| DORLIMOMAB ARITOX | CHEMBL2109124 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| ELX-02 | CHEMBL4297744 | 80S Ribosome modulator | MODULATOR | ChEMBL |
| MT-3724 | CHEMBL4297789 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| TAPLITUMOMAB PAPTOX | CHEMBL2107890 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| TELIMOMAB ARITOX | CHEMBL2108790 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| ZOLIMOMAB ARITOX | CHEMBL2108785 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
Trials38
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07523581 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT05448755 | ELX-02 | PHASE2 | 2026-02-24 | ClinicalTrials.gov |
| NCT04336826 | ATALUREN | PHASE2 | 2024-04-01 | ClinicalTrials.gov |
| NCT04135495 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04126473 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04117880 | ATALUREN | PHASE2 | ClinicalTrials.gov | |
| NCT04069260 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04014530 | ATALUREN | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT03796637 | ATALUREN | PHASE2 | 2022-04-05 | ClinicalTrials.gov |
| NCT03645395 | MT-3724 | PHASE2 | 2022-08-16 | ClinicalTrials.gov |
1 to 10 of 38
See all 38 trialsNIH grants1,187
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | RPL11 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 8 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 8 | 2025 |
| ZIACP010144 | Clinical Genetic Studies of Familial and Hereditary Cancer Syndromes | 7 | 2025 |
| P01CA163222 | Targetable epigenetic and transcriptional mechanisms in melanoma thatshape the microenvironment | 4 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 4 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 4 | 2025 |
| P30CA046592 | University of Michigan Rogel Cancer Center Support Grant 2023-2028 | 4 | 2025 |
| R01AR043369 | MITF from control of pigmentation to melanoma risk | 4 | 2025 |
| R01DK103794 | Systematic Genetic Dissection of Human Erythropoiesis | 4 | 2025 |
| P30CA010815 | Consolidated Basic Cancer Research Program | 3 | 2025 |
1 to 10 of 1,187Source NIH's project files
See all 1,187 nih grantsPapers1,885
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Ribosomal Protein L11 Mediates Antiviral Defense via Activation of Apoptosis in Bombyx mori. | J Agric Food Chem | 2026 | 42677657 | PubTator, text mining | PubMed |
| MYC-driven BYSL overexpression promotes hepatocellular carcinoma by suppressing nucleolar stress and inactivating the RPL5/RPL11-MDM2-p53 pathway. | Cell Signal | 2026 | 42575394 | PubTator, text mining | PubMed |
| RPS5 modulates inflammatory response and angiogenesis in coronary heart disease through NF-κB signaling activation. | Mol Cell Biochem | 2026 | 42440233 | PubTator, text mining | PubMed |
| KDM4D enhances radiosensitivity in esophageal squamous cell carcinoma through the SRBD1/RPL11/c-Myc/WIP1/CHK1 axis. | Am J Transl Res | 2026 | 42325777 | PubTator, text mining | PubMed |
| Structural Insights into the Cyclic Peptide Antibiotic Thiostrepton via NMR Spectroscopy. | J Phys Chem A | 2026 | 42299055 | PubTator, text mining | PubMed |
| Integrative transcriptomic and systems biology analysis of public SLE datasets identifies immune regulatory pathways. | J Comput Aided Mol Des | 2026 | 42295464 | PubTator, text mining | PubMed |
| Mutant KRAS-driven selective mRNA translation reveals mechanisms and therapeutic vulnerabilities in cancer. | Cell Rep | 2026 | 42284146 | PubTator, text mining | PubMed |
| MAZ-driven MRPL11 links mitochondrial homeostasis to AKT/mTOR signaling and promotes pancreatic ductal adenocarcinoma progression. | Biochim Biophys Acta Mol Basis Dis | 2026 | 42263886 | PubTator, text mining | PubMed |
| A RiboCancer cell line panel reveals that CLL-associated Rps15 mutations translationally rewire transcription through codon-specific tRNA accommodation defects. | Hemasphere | 2026 | 42255948 | PubTator, text mining | PubMed |
| Single-cell transcriptomics and machine learning unveil liquid-liquid phase separation-related biomarkers in HPV-positive cervical cancer. | Infect Agent Cancer | 2026 | 42251432 | PubTator, text mining | PubMed |
1 to 10 of 1,885
See all 1,885 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/6135
GET https://conductscience.org/api/genes/v1/6135/patents?page=2